Lecanemab (Leqembi)

Lecanemab (Leqembi) is an experimental medication designed to slow early Alzheimer's disease by targeting and removing amyloid plaques—protein accumulations in the brain associated with the condition. By reducing these plaques, it aims to slow cognitive decline and preserve memory and functioning. The drug is given through intravenous infusions, typically every few weeks, and is currently approved for certain patients as part of ongoing research and regulatory review. While promising, Lecanemab's effectiveness and safety are still being studied, and it represents an important step in developing treatments for Alzheimer's disease.